MIT researchers achieved a groundbreaking advance that could transform brain disease treatment. They developed microscopic, wireless bioelectronic implants that doctors can inject into the bloodstream, allowing the devices to self-navigate to targeted brain regions without surgery. These next-generation devices could one day provide non-invasive treatment for devastating neurological disorders, including Alzheimer’s disease, multiple sclerosis, and brain tumors.
A Leap Toward Non-Surgical Brain Therapy
In a recent study published in Nature Biotechnology, the MIT team demonstrated that, after they injected the microscopic implants into the bloodstream of mice, the implants could locate and self-implant in a precise brain region without human guidance. Once in place, the team wirelessly powered the devices to deliver electrical stimulation, or neuromodulation, directly to target neurons. Researchers have already shown that neuromodulation can effectively treat neurological disorders and control brain inflammation, a key factor in many brain diseases.
Crucially, the implants are integrated with living biological cells before injection. This biohybrid approach allows them to evade the body’s immune defenses, cross the blood-brain barrier intact, and maintain the brain’s natural protection.
Introducing “Circulatronics”: A New Frontier in Neuroengineering
As per the MIT Press release, the MIT researchers have named this revolutionary technology “circulatronics.” It enables precise, localized neuromodulation deep within the brain, achieving accuracy to within a few microns of the target area—without damaging surrounding neurons.
“Traditional brain implants cost hundreds of thousands of dollars and require risky surgeries,” explained Dr. Deblina Sarkar, senior author of the study and AT&T Career Development Associate Professor at the MIT Media Lab. “Our circulatronics technology eliminates the need for surgery, making therapeutic brain implants far more accessible.”
Dr. Sarkar collaborated with lead author Shubham Yadav, an MIT graduate student, and researchers from Wellesley College and Harvard University.
Building Hybrid Bioelectronic Implants
The MIT team has spent over six years developing circulatronics. Each implant, a billionth the length of a grain of rice, consists of organic semiconducting polymer layers sandwiched between metallic layers, forming a robust electronic heterostructure.
Using CMOS-compatible fabrication at MIT.nano, the team integrated these micro-devices with living cells, creating hybrid cell-electronics units. Initially, they faced challenges in maintaining functionality after detaching the devices from silicon wafers. “It took us over a year to solve that problem,” said Dr. Sarkar.
The implants’ high wireless power efficiency allows them to function deep within the brain, enabling remote neuromodulation through near-infrared light transmitted externally.
Harnessing Immune Cells for Precision Targeting
In this study, the researchers bonded the electronics to immune cells (monocytes), which naturally seek out inflammation. These hybrid devices were then tracked with a fluorescent dye as they crossed the blood-brain barrier and self-implanted at inflamed brain sites.
“Our hybrid design merges the precision of electronics with the transport and sensing capabilities of living cells,” said Sarkar. “The cells camouflage the electronics, allowing them to move seamlessly through the bloodstream and reach their targets without triggering immune rejection.”
Over four years, the team refined this cellular integration method to autonomously and non-invasively cross the blood-brain barrier, a feat previously considered nearly impossible.
Safe Integration with Brain Cells
Because of their microscopic size, the circulatronics devices can self-implant at multiple sites and conform to the exact shape of the target region. They coexist with neurons without disrupting cognitive or motor function, as confirmed through extensive biocompatibility testing.
After implantation, clinicians can activate the devices remotely using electromagnetic waves or near-infrared light, allowing precise neural stimulation for therapy.
Toward Treating Deadly Brain Diseases
The Sarkar Lab is now focusing on adapting this platform to treat brain cancer, chronic pain, and neurodegenerative diseases. The technology could be especially beneficial for hard-to-reach tumors, such as glioblastoma and diffuse intrinsic pontine glioma (DIPG)—conditions that often cannot be surgically removed.
“This is a platform technology that could be applied to multiple brain diseases and even extended to other organs,” said Sarkar.
The team aims to begin clinical trials within three years through their newly launched startup, Cahira Technologies. They also plan to integrate additional nanoelectronic circuits for sensing, feedback, and data analysis, creating a foundation for synthetic electronic neurons.
A Vision for the Future
“Our tiny electronic devices seamlessly integrate with neurons, creating a unique brain-computer symbiosis,” Sarkar said. “We are dedicated to using this technology to treat conditions where drugs and standard therapies fail—easing human suffering and envisioning a future where humans can transcend diseases and biological limitations.”